Best Ophthalmology Companies in Germany
The 42 best Ophthalmology companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CureVac.
- Growth Foreseen for Ophthalmology Sector
Ranked: Best Ophthalmology companies in Germany
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1stQ Manufacturer of intraocular lenses, ophthalmic surgical devices, and related instruments | — | — | — | — | WordPress Block EditorWordPressMySQL+22 | Top 10M | — | — |
| 2 | ALBOMED Manufacturer and developer of viscoelastics for medical use | — | — | 13 | Sven Reese Managing Director | WordPressMySQLPHP+25 | Top 10M | 8 patents Patents concentrated in health & consumer products | — |
| 3 | Alsanza A portfolio of Intraocular lenses, viscoelastics and Eye Irrigating Solutions | — | — | 9 | — | DrupalPHPAnimate.css+7 | Top 50M | — | — |
| 4 | Curexsys Developer of therapeutics to treat age-related diseases | — | — | 11 | Jens Gruber Co-Founder | — | — | — | — |
| 5 | Gebauer Medizintechnik Developer of devices for corneal transplantation and refractive surgery | — | — | — | Steffen Gebauer Managing Director | — | — | — | — |
| 6 | HumanOptics Intraocular implants for ophthalmic surgeries | — | — | 121 | — | WordPressApple iCloud MailMicrosoft 365+23 | Top 10M | 43 patents Intraocular lens storage, handling, and customized ophthalmic implant manufacturing systems. | — |
| 7 | HYLO Provider of daily eye care products | — | — | — | Frank Holzer Managing Director | Node.jsUbuntuTailwind CSS+10 | Top 5M | — | — |
| 8 | Imedos Developer of medical device systems for retinal vascular analysis | — | — | — | Walthard Vilser Co-Founder & Co-CEO | — | — | 15 patents Quantitative retinal imaging and analysis for vascular diagnostics | — |
Top 12 Ophthalmology companies in Germany
#1
Acquired · Tubingen, Baden Wurttemberg · founded 2000 · 648 employees$975.3Mraised▾
Developer of mRNA-based therapeutics against cancer and infectious diseases. It has developed RNAntibody to enable the expression of functional antibodies and antibody-like proteins from mRNA. The lead product includes CV9104, an investigational therapeutic vaccine to treat prostate cancer. The vaccine is injected into the skin to stimulate the body's immune system to destroy prostate cancer cells. The company's other product includes CV8102 for cutaneous myeloma and CV9202 used to treat patients with non-small cell lung cancer.
- Sep 2020Grant (prize money)$299M
- Jul 2020Series F$126M
- Jul 2020Series F$171M
- Jul 2020Conventional Debt$84.3M
#2
Seed · Kaiserslautern, Rhineland Palatinate · founded 2017 · 3 employees$250Kraised▾
AkknaTek is a developer of solutions for cataract surgery. The company has developed a device called Lens Reviewer for postoperative management and monitoring of dislocated intraocular lens (IOL) to avoid post-cataract refractive surgeries.
- Feb 2023Grant (prize money)—
- Oct 2020Seed$250K
#3
Series G · Wurzburg, Bavaria · founded 1998 · 5 employees$62.7Mraised▾
Developer of therapeutics for retina and brain diseases. It offers a lead product Ronopterin which is a selective iNOS inhibitor which reduces inflammatory response and edema formation for the treatment of traumatic brain injury and diabetic retinopathy.
- Jul 2019Series G$10.7M
- Jan 2016Series G$21.8M
- Jun 2013Series F$6.5M
- May 2009Series D$6M
#4
Series A · Berlin, Berlin · founded 2017 · 17 employees$17.4Mraised▾
Developer of digital therapeutics for myopia. The technology delivers light stimulation to specific photosensitive cells on the retina that modulate dopamine that helps in the regulation of eye growth. It also provides Myopiax a mobile application for children, providing fun and treatment.
- Jul 2021Series A$14.2M
- Jun 2019Seed$1.3M
- 2018Grant (prize money)—
#5
Series F · Munich, Bavaria · founded 1998 · 3 employees$158.1Mraised▾
Isarna Therapeutics develops TGF-B inhibitors that stimulate the human immune system to effectively treat ophthalmic, fibrotic diseases cancer. Its lead product ISTH0036 for ophthalmology is undergoing Phase 1 trials. Other candidates include ISTH1106 for fibrosis, ISTH0047, and ISTH1047 for oncology which are in pre-clinical stage. Its leading candidate ISTH0036 is a locked nucleic acid-modified antisense oligonucleotide selectively targeting the messenger ribonucleic acid (mRNA) of TGF-β2. The company received FDA orphan drug designation for ISTH0036, for the prevention of scarring post glaucoma filtration surgery.
- Apr 2014Series F$7.6M
- Jan 2014Series F$17.8M
- Jan 2012Series F$11M
- Jul 2011Series E$11.6M
#6
Series C · Heidelberg, Baden-wurttemberg · founded 2007 · 30 employees$115Mraised▾
Novaliq is developing reformulated drug products based on semi-fluorinated alkanesfor ocuar therapeutics. Its proprietary platform uses semi-fluorinated alkanes as a delivery alternative to water, and drug carriers being perfluorohexyloctane and perfluorobutylpentane. The company has an approved OTC product called NovaTears to cure a mild dry eye. In addition, the company has another compound called CyclASol for a severe dry eye which in phase 3 trials. Its a non-aqueous and preservative-free formulation containing cyclosporine.
- Oct 2018Series C$53M
- Jan 2016Grant (prize money)$162.1K
- Apr 2013Series B$18.1M
- May 2012Series A$5.1M
#7
Series C · Hannover, Lower Saxony · founded 2009 · 9 employees$8.5Mraised▾
Implandata Ophthalmic Products GmbH (IOP) is a medical device company. IOP has developed a technology for 24 hour measurement of intraocular pressure, for monitoring and treatment of glaucoma patients. The Eyemate system consists of an implantable, biocompatible microsensor for the telemetric measurement of intraocular pressure,
- May 2018Series C—
- Jan 2016Grant (prize money)$270.6K
- Oct 2014Series B$3.8M
- Aug 2012Series A$2M
#8
Series B · Reutlingen, Baden Wurttemberg · founded 2003 · 10 employees$46.4Mraised▾
Retina Implant is a developer of subretinal implants for retinitis pigmentosa, partially sighted and blind patients. It primarily focuses on the development of electronic subretinal implants which picks up light via 1,500 pixels. The signal is boosted by a coil implanted in the skin behind the ear and sent back to the bipolar cells still active on the retina, which in turn send an image to the brain through regular neural circuits.
- Feb 2016Series B$28.4M
- Mar 2011Series A$18M
#9
Series B · Kleinmachnow, Brandenburg · founded 2007 · 4 employees$5.4Mraised▾
EBS Technologies is developing Eyetronic therapy, an electrical optic nerve stimulation technology for the treatment of patients suffering from glaucoma and other conditions affecting the optic nerve. It applies gentle electrical pulses to the optic nerve cells, thereby preventing further cell degeneration and reactivating nerve tissue, resulting in restored vision. The company has received CE mark approval.
- Aug 2015Series B$1.2M
- Feb 2015Series B$281.8K
- Jun 2013Series B$3.9M
- Mar 2009Seed—
#10
Funding Raised · Tubingen, Baden Wurttemberg · founded 2011$3.2Mraised▾
Developer of therapeutics for the treatment of disabling eye indications. The company's product include Remofuscin, is being developed for the treatment of Stargardt disease and dry age-related macular degeneration, with a unique characteristic of removing lipofuscin from living cells.
- Dec 2017Grant (prize money)$3.2M
#11
Series A · Berlin, Berlin · founded 2010 · 2 employees$857.6Kraised▾
Caterna Vision develops digital therapies for treating eye disorders. The first product is Caterna eye training for treatment of a functional optical deficit among children (amblyopia). It is used as a "second-line" complementary treatment to occlusion therapy. The products are offered through an online therapy platform and can accessed via PCs. After diagnosis and consultation with an ophthalmologist the type, extent and duration of the child’s vision exercises are determined. Based on the diagnosis an appropriate solution is referred to the patient which can be accessed online. The company charges a subscription fee for the sessions.
- Jul 2017Series A—
- May 2014Seed—
- Jan 2011Seed$857.6K
#12
Deadpooled · Dresden, Saxony · founded 2013$53.2Kraised▾
Hapticom is developing, haptiPad, a smart pad enabling mobile communication and access to digital information for blind and deafblind people. The device can help visual impaired people to talk to everyone worldwide and gain information without restrictions.
- Jul 2015Grant (prize money)$54.8K
- Feb 2015Grant (prize money)$56.5K
- Aug 2013Seed$53.2K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Ophthalmology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices is moving in Germany
A read on the academic research around Medical Devices — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 420 Germany-affiliated papers.
- Technical University of Munich30
- Universität Hamburg24
- RWTH Aachen University20
- Karlsruhe Institute of Technology15
- University of Rostock14
- Robot5→18
- Surgical robot4→14
- Biomedical engineering3→6
- Surgical robot7→13
- Robot9→14
- Risk analysis (engineering)1→4
- Surgery1→4
- Surgical instrument1→4
- Health care2→12
- Surgical robot4→10
- Biomedical engineering2→7
- Patient safety2→7
- Quality (philosophy)3→7
Where medical devices is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing medical devices patents in Germany
Germany medical devices patent filing is cooling — 97,357 filings from 8,000 assignees (2016–2025), led by Siemens, Sanofi Aventis Deutschland, Aesculap; annual filings 10817→8851.
- Siemens18002
- Sanofi Aventis Deutschland10208
- Aesculap4900
- Zeiss CARL Meditec4287
- Fresenius Medical CARE Deutschla4185
- Hoffmann LA Roche2972
- Fresenius Medical CARE DE2688
- Biotronik SE & KG2562
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.